Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

ClinicalTrials.gov ID: NCT03557307

Public ClinicalTrials.gov record NCT03557307. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients With Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.

Study identification

NCT ID
NCT03557307
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
598 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2018
Primary completion
Apr 15, 2021
Completion
Mar 23, 2022
Last update posted
Jun 5, 2023

2018 – 2022

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
23
Facility City State ZIP Site status
Research Site Flagstaff Arizona 86001
Research Site Los Angeles California 90025
Research Site Aurora Colorado 80045
Research Site Newark Delaware 19713
Research Site Tampa Florida 33607
Research Site Winter Park Florida 32789-4681
Research Site Albany Georgia 31707
Research Site Atlanta Georgia 30322
Research Site Savannah Georgia 31405
Research Site Normal Illinois 61761
Research Site Georgetown Kentucky 40324
Research Site Lakeside Park Kentucky 41017
Research Site Ann Arbor Michigan 48109
Research Site Minneapolis Minnesota 55402
Research Site Saint Paul Minnesota 55101
Research Site St Louis Missouri 63156
Research Site New York New York 10016
Research Site Chapel Hill North Carolina 27599
Research Site Greenville North Carolina 27834
Research Site Wilmington North Carolina 28401
Research Site Winston-Salem North Carolina 27104
Research Site DuBois Pennsylvania 15801
Research Site North Charleston South Carolina 29406

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03557307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 5, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03557307 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →